# The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication

> **NCT04527055** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **National Cheng-Kung University Hospital** · enrollment: 312 (estimated)

## Conditions studied

- Helicobacter Pylori Infection
- Dysbiosis
- Probiotics

## Interventions

- **DRUG:** Bismuth Subcitrate 120 MG Oral Tablet
- **DIETARY_SUPPLEMENT:** Lactobacillus acidophilus and Bifidobacterium lactis Bb12
- **DRUG:** Esomeprazole 40mg
- **DRUG:** Metronidazole 250 MG
- **DRUG:** Tetracycline Pill

## Key facts

- **NCT ID:** NCT04527055
- **Lead sponsor:** National Cheng-Kung University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2020-05-06
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04527055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04527055, "The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therapy in First-line H. Pylori Eradication". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT04527055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*